AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
2022-03-11
AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved the oral JAK1 inhibitor Rinvoq (Rinvoq, generic name: upadacitinib, upadacitinib extended-release tablets) for the treatment of adults and adults aged 12 and Refractory, moderate to severe atopic dermatitis (AD) in the above children and adolescents. This approval marks the first indication that Rinvoq has been approved in China.
Rinvoq is specifically indicated for: children and adolescents (≥12 years) and adults with refractory, moderate-to-severe atopic dermatitis (AD) who have not responded well to or are not suitable for other systemic therapy (eg, hormones or biologics) patient. In terms of medication, for children, adolescents and adults with a body weight of ≥ 40 kg and an age of ≥ 12 years, the starting dose is 15 mg once a day. The dose can be increased to 30 mg once daily in children and adolescents and adults under 65 years of age who are unresponsive.
So far, Rinvoq has been approved in the EU for 4 indications (rheumatoid arthritis [RA], psoriatic arthritis [PsA], ankylosing spondylitis [AS], atopic dermatitis [AD]), in 3 indications (RA, PsA, AD) have been approved in the United States. Rinvoq 15mg dose is suitable for the treatment of all the above indications, while Rinvoq 30mg is only suitable for the treatment of AD.
